Loading
A prevention trial for the group who get these cancers worst: people on long-term immunosuppression, for whom squamous cell carcinoma is not an event but a recurring condition.
Organ transplant recipients and others on long-term immunosuppression develop cutaneous squamous cell carcinoma at many times the general rate, and they develop them repeatedly, which turns a curable cancer into a chronic surgical burden. SPOT-IT, sponsored by Cardiff University with a target of 673 participants and a registered end date of 31 December 2031, tests topical field treatment as prevention rather than as treatment of an established lesion. NICE NG34 recommendation 1.1.1 names immunosuppressed people among the groups who should take extra care in the sun; SPOT-IT asks whether the NHS can do more than advise them.
Criteria as posted are in the stored snapshot. Read 2026-10-07.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Velindre Cancer Centre, Cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags uk, skin, recruiting.
Shares Cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags uk, skin, prevention.
Shares Cutaneous squamous cell carcinoma, Skin cancer (all types) and the tags uk, skin.
Shares Cutaneous squamous cell carcinoma, Skin cancer (all types) and the tag uk.
Shares Skin cancer (all types) and the tags uk, skin, recruiting.
Shares Skin cancer (all types) and the tags uk, skin.
Shares Skin cancer (all types) and the tags uk, skin.
Shares Skin cancer (all types) and the tags uk, skin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/